SEHK:867Pharmaceuticals
Assessing China Medical System Holdings (SEHK:867) Valuation After CMS D017 Clinical Trial Approval
China Medical System Holdings (SEHK:867) has secured approval from China's National Medical Products Administration to start clinical trials for CMS-D017, an oral complement factor B inhibitor targeting paroxysmal nocturnal hemoglobinuria.
See our latest analysis for China Medical System Holdings.
Trading at HK$14.58, China Medical System Holdings has seen firm momentum recently, with a 7 day share price return of 4.59%, a 30 day share price return of 7.44%, and a 1 year total shareholder...